ITGB2 and atherosclerosis: Treatment with blocking anti-Mac-1 antibodies (69), depletion of Mac-1 expressing cells (128), and treatment with a specific inhibitor of this interaction—the peptide M7 (56)—protected from de novo atherosclerosis in Ldlr−/− mice on a high fat diet and reduced the number of lesional leukocytes, suggesting that this interaction may be a driver of leukocyte mobilization into the plaque.